Proteon Therapeutics to Participate in Two Upcoming Investor Conferences

WALTHAM, Mass., Nov. 09, 2016 -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will participate in the following upcoming investor conferences:

• A presentation by management at the Stifel 2016 Healthcare Conference in New York City on Wednesday, November 16, 2016, at 8:00 am ET; and
   
• The Oppenheimer Life Sciences Summit in New York City on November 29, 2016.

About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials, PATENCY-1 and PATENCY-2, in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis, and two Phase 1 clinical trials in patients with peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.

Investor Relations Contact
George Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]  

Media Contact
Cara Mayfield, Ten Bridge Communications
857-242-1872
[email protected]